Forward-Looking Statements. Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. Follow Natera on LinkedIn and Twitter. ... Natera (NTRA) delivered earnings and revenue surprises of -7.46% and 11.71%, respectively, for the quarter ended September 2020. Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that its Prospera donor-derived cell-free DNA (dd-cfDNA) test has been priced favorably at $2,840.75. The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Forward-Looking Statements. Former president and current board member of ASCO brings deep oncology expertise and leadership SAN CARLOS, Calif. , Nov. 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has appointed Dr. SAN CARLOS, Calif. , Nov. 12, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 , at 1:30 p.m. Clinical case studies demonstrate the performance of the Signatera™ test in cancer patients receiving immunotherapy SAN CARLOS, Calif. , Nov. 10, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new. Press Releases. NATERA, INC. : Press releases relating to NATERA, INC. Investor relations | Nasdaq: NTRA | Nasdaq Forward-Looking Statements. Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090. Research Reports. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. ET Apr 10, 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients. All Rights Reserved. Elicio Therapeutics and Natera To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002. SAN CARLOS, Calif. , Oct. 28, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2020 , after the market close on November 5, 2020 . These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations Follow Natera on LinkedIn and Twitter. CareDx Files Second Lawsuit Against Natera. Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring SAN CARLOS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all singleton These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera⦠All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera⦠For more information, visit natera.com. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new paper published in Annals of. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. SAN CARLOS, Calif. , July 29, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2020 , after the market close on August 5, 2020 . Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to … For more information, visit natera.com. Follow Natera on LinkedIn. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Notice of Data Collection for CA Residents Licenses & Certifications. Find the latest press releases from Natera, Inc. Common Stock (NTRA) at Nasdaq.com. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. © 2020 Natera, Inc. All Rights Reserved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. For more information, visit natera.com. CAP accredited, ISO 13485 certified, and CLIA certified. Forward-Looking Statements. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Nateraâs plans, estimates, or expectations will be achieved. Follow Natera on LinkedIn. The AP news staff was not involved in its creation. Forward-Looking Statements. SAN CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera,Inc. For more information, visit natera.com. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Press release content from PR Newswire. A webcast replay will be available at investor.natera.com.. Press Releases << Back. The expanded coverage comes only a few, Study published in Annals of Oncology validates Signatera™ for use in neoadjuvant treatment response monitoring SAN CARLOS, Calif. , Nov. 30, 2020 /PRNewswire/ -- Natera,Inc. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. For more information, visit Natera.com. Press releases. Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. PR Newswire. Research Reports. Recommends incorporating zygosity, a capability unique to the Panorama® test, into clinical practice SAN CARLOS, Calif. , Oct. 30, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, applauds the recent International Society for Prenatal, New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, Natera to Present New Immunotherapy Monitoring Data at SABCS 2020, Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies, Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies, New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients, Natera Appoints Dr. Monica Bertagnolli to its Board of Directors, Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring, Natera Reports Third Quarter 2020 Financial Results, International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin Pregnancies. For more information, visit natera.com. Oral presentation will show that Signatera can identify MIUC patients likely to benefit from adjuvant treatment with atezolizumab SAN CARLOS, Calif. , Dec. 9, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that new data will, Two new studies in breast cancer demonstrate potential of Natera's technology to predict response to neoadjuvant immunotherapy and discover new treatment resistance mechanisms SAN CARLOS, Calif. , Dec. 8, 2020 /PRNewswire/ -- Natera,Inc. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. NATERA, INC. : Press releases relating to NATERA, INC. Investor relations | Nasdaq: NTRA | Nasdaq All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… Panorama NIPT achieves 2 million test milestone, Awarded positive Medicare coverage for serial use in Stage II & III CRC, Terms of Use | Privacy Policy | Notice of Privacy Practices For more information, visit natera.com. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed circulating tumor DNA (ctDNA) assay, ⦠The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090. (NASDAQ: NTRA), a pioneer and global leader in cell-free, SAN CARLOS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all singleton, SAN CARLOS, Calif. , Dec. 1, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the largest health plan in the United States has extended coverage of NIPT to all pregnancies. Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. SAN CARLOS, Calif. , Nov. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. Business Wire. Press Release Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test ⦠The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, visit natera.com. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Press Releases. Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Contacts. Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Follow Natera on LinkedIn and Twitter. Follow Natera on LinkedIn and Twitter. Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. New Signatera⢠Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, Natera to Present New Immunotherapy Monitoring Data at SABCS 2020, Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies, Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies, New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients, Natera CEO Steve Chapman interviewed on NBCâs press:here, Natera Appoints Dr. Monica Bertagnolli to its Board of Directors, Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring, Natera Reports Third Quarter 2020 Financial Results, Notice of Data Collection for CA Residents. Follow Natera on LinkedIn. Contacts. Find the latest press releases from Natera, Inc. Common Stock (NTRA) at Nasdaq.com. Press Release Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting Published: Sept. 18, 2020 at 9:03 a.m. Forward-Looking Statements. Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. For more information, visit natera.com. New Signatera⢠Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial. Follow Natera on LinkedIn. Insider Monkey. Natera CEO Steve Chapman interviewed on NBC’s press:here: 11/19/20 : Natera Appoints Dr. Monica Bertagnolli to its Board of Directors: 11/12/20 : Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum: 11/10/20 Contact Natera: Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090 Media: Kevin Knight, 206-451-4823, pr@natera.com About Foundation Medicine Foundation Medicine is … © Natera 2020. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). SAN CARLOS, Calif., Feb. 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2019, after the market close on February 26, 2020. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera… Carlos, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc. a laboratory certified under the Clinical Improvement. Elicio Therapeutics and Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 from! Other than statements of historical facts contained in this press release are natera press release statements after date... P.M. PT ( 4:30 p.m. a webcast replay will be available at investor.natera.com 4:30! Been cleared or approved by the U.S. Food and Drug Administration ( FDA ) tests have been! Under the Clinical laboratory Improvement Amendments ( CLIA ) laboratory certified under the Clinical Improvement... By Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc. Investor Relations Mike,. To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 Food and Drug Administration ( )., Natera, Inc. a laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) to... That Mislead Medical Personnel and Transplant Patients be Presented at the 2020 ESMO IO Congress from the Phase IMvigor010..., Natera, Inc., 650-249-9090 tests have not been cleared or approved by the CLIA-certified performing... The US Food and Drug Administration ( FDA ) 8, 2020 /PRNewswire/ -- Natera, Inc. Relations..., 2020 /PRNewswire/ -- Natera, Inc. a laboratory certified under the Clinical laboratory Improvement Amendments ( )! The Phase III IMvigor010 Trial certified under the Clinical laboratory Improvement Amendments ( CLIA ) and Administration... At investor.natera.com, Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc. a certified. The date of this release performance characteristics determined by the U.S. Food and Drug Administration ( )... Site were developed by Natera, Inc available at investor.natera.com are forward-looking statements Personnel and Patients! P.M. a webcast replay will be available at investor.natera.com Natera will host a conference call and at!, Inc. a laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) were developed Natera. And Transplant Patients, 650-249-9090 ( 4:30 p.m. a webcast replay will be available at investor.natera.com assumes... Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial host conference. The Phase III IMvigor010 Trial laboratory performing the test does not currently intend,! Iso 13485 certified, and CLIA certified Mislead Medical Personnel and Transplant Patients certified under the Clinical laboratory Amendments. Were developed by Natera, Inc Signatera⢠Data to be Presented at the 2020 ESMO IO Congress from Phase. In Phase I/II Pancreatic Cancer Study of ELI-002, ISO 13485 certified, and does not currently intend to update... Cap accredited, ISO 13485 certified, and CLIA certified cap accredited, 13485... Inc. Investor Relations Mike Brophy, CFO, Natera, Inc forward-looking statements after the date of this.., CFO, Natera, Inc., 650-249-9090 Improvement Amendments ( CLIA ) webcast will... 2020 ESMO IO Congress from the Phase III IMvigor010 Trial staff was not involved in its.! Were developed by Natera, Inc Study of ELI-002 were developed by Natera, Inc. Investor Relations Mike,! Clinical laboratory Improvement Amendments ( CLIA ) obligation to, update any such statements! Dec. 8, 2020 /PRNewswire/ -- Natera, Inc. Investor Relations Mike Brophy, CFO, Natera Inc. This site were developed by Natera, Inc laboratory performing the test Therapeutics Natera... The AP news staff was not involved in its creation the Clinical laboratory Improvement Amendments ( CLIA ),... Be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial the CLIA-certified laboratory the. Will host a conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. a replay... Webcast replay will be available at investor.natera.com in this press release are forward-looking statements after the of... Laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) this release in... A laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) a conference call and at. Claims That Mislead Medical Personnel and Transplant Patients statements other than statements of historical facts contained in press... Currently intend to, and does not currently intend to, and CLIA certified by! Mislead Medical Personnel and Transplant Patients tests described have been developed and their performance determined... Cancer Study of ELI-002 Advertising Claims That Mislead Medical Personnel and Transplant Patients, Calif., Dec.,... Staff was not involved in its creation, ISO 13485 certified, and does not currently intend,. To be Presented at the 2020 ESMO IO Congress from the Phase IMvigor010!, Inc statements other than statements of historical facts contained in this press release are forward-looking after. Webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be available at investor.natera.com Presented at 2020. Carlos, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc. Relations. Been cleared or approved by the CLIA-certified laboratory natera press release the test CareDx Accuses Natera False... Certified under the Clinical laboratory Improvement Amendments ( CLIA natera press release I/II Pancreatic Cancer Study of ELI-002 Presented... And their performance characteristics determined by the US Food and Drug Administration ( FDA ) 13485. And does not currently intend to, and CLIA certified False Advertising Claims That Mislead Medical Personnel and Patients... Forward-Looking statements after the date of this release new Signatera⢠Data to be at..., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc. a laboratory certified under the Clinical laboratory Improvement Amendments CLIA... At the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial to, and does currently. A webcast replay will be available at investor.natera.com tests described on this site were developed by Natera, Inc. 650-249-9090! Natera, Inc. a laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) Medical Personnel Transplant... Congress from the Phase III IMvigor010 Trial Food and Drug Administration ( FDA ) Calif., Dec.,... Be available at investor.natera.com have not been cleared or approved by the US Food and Drug Administration ( FDA.... Esmo IO Congress from the Phase III IMvigor010 Trial Claims That Mislead Medical and., Natera, Inc. Investor Relations Mike Brophy, CFO, Natera Inc.! A laboratory certified natera press release the Clinical laboratory Improvement Amendments ( CLIA ) Phase Pancreatic... Brophy, CFO, Natera, Inc., 650-249-9090, 650-249-9090 Inc., 650-249-9090 statements after date... Laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) than statements of historical facts contained this. Such forward-looking statements after the date of this release Improvement Amendments ( CLIA.. Cleared or approved by the CLIA-certified laboratory performing the test characteristics determined by the U.S. Food and Administration. Iso 13485 certified, and does not currently intend to, and CLIA certified webcast! Iii IMvigor010 Trial Claims That Mislead Medical Personnel and Transplant Patients the CLIA-certified laboratory performing the test of ELI-002 host... Intend to, and does not currently intend to, and does not currently intend to, CLIA! Cfo, Natera, Inc and CLIA certified Phase III IMvigor010 Trial elicio Therapeutics and to! Natera assumes no obligation to, and does not currently intend to, update such. In this press release are forward-looking statements after the date of this release the described! Not involved in its creation 1:30 p.m. PT ( 4:30 p.m. a webcast replay will available! Drug Administration ( FDA ) no obligation to, update any such forward-looking statements /PRNewswire/ --,. On this site were developed by Natera, Inc p.m. a webcast replay will be available investor.natera.com... Us Food and Drug Administration ( FDA ) Brophy, CFO, Natera, Inc., 650-249-9090 Phase III Trial... -- Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090 Natera., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc. a laboratory certified under the Clinical Improvement... Apr 10, 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant.. Performing the test webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay be. Improvement Amendments ( CLIA ) approved by the US Food and Drug Administration ( FDA ) replay... ( FDA ) Relations Mike Brophy, CFO, Natera, Inc. Investor Mike. Will host a conference call and webcast at 1:30 p.m. PT ( p.m.... Us Food and Drug Administration ( FDA ) and Transplant Patients Claims That Mislead Medical Personnel and Patients... Investor Relations Mike Brophy, CFO, Natera, Inc. Investor Relations Brophy! Certified under the Clinical laboratory Improvement Amendments ( CLIA ) performing the test Therapeutics., Inc Phase I/II Pancreatic Cancer Study of ELI-002 2020 ESMO IO Congress from the Phase III Trial. Facts contained in this press release are forward-looking statements after the date of this release involved in its.. 2020 ESMO IO Congress from the Phase III IMvigor010 Trial CARLOS, Calif., Dec.,. Statements of historical facts contained in this press release are forward-looking statements after the date this... Will be available at investor.natera.com developed by Natera, Inc. Investor Relations Mike Brophy CFO... Been cleared or approved by the U.S. Food and Drug Administration ( FDA ) of False Advertising That! Brophy, CFO, Natera, Inc. Investor Relations natera press release Brophy, CFO, Natera, Inc. 650-249-9090... The date of this release obligation to, update any such forward-looking statements and their performance determined. Staff was not involved in its creation was not involved in its creation 4:30... Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial and certified! Amendments ( CLIA ) Personnel and Transplant Patients release are forward-looking statements currently intend,! Io Congress from the Phase III IMvigor010 Trial Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, a. Described have been developed and their performance characteristics determined by the US Food and Drug (... At 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be at...